At a glance
ClinicalIndex Comparison RecordN/ACompleted· 16 enrolled
Drug / intervention
CyberKnifedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mono-Center Phase ǀ Study on Dose Escalation of Stereotactic Body Radiotherapy (SBRT) Treating Pancreatic Cancer Patients With CyberKnife
In Brief
A clinical study evaluating CyberKnife for Pancreatic Tumor. Completed, enrolled 16 participants across 2 sites.
Detailed Summary
The maximum tolerated dose on locally advanced unresectable pancreatic tumor treated with CyberKnife SBRT will be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Tumor
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedMar 2016
Primary CompletionDec 2020
TodayJul 2026
First PostedMar 23, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.3 years ago
Interventions
CyberKnifedevice
Radiation Therapy